JPMorgan analyst Rachel Vatnsdal initiated coverage of Caris Life Sciences (CAI) with an Overweight rating and $31 price target The firm says Caris is a leading diagnostics company focused on enabling precision medicine. The company’s whole exome sequencing and whole transcriptome sequencing technology targets significantly more genes than competitive assays, the analyst tells investors in a research note. JPMorgan believes Caris recently reached an inflection point with FDA approval of its tissue-based therapy selection assay.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAI:
- Caris Life Sciences initiated with a Buy at BofA
- Caris Life Sciences initiated with a Buy at Guggenheim
- Caris Life Sciences: Strong Market Position and Growth Potential Justify Buy Rating
- Caris Life Sciences publishes Assure liquid biopsy platform study
- Caris Life Sciences vice chairman Brille buys 30,000 common shares